ALXN—FDA delays review of Kanuma (sebelipase alfa) by three months due to CMC issues (new PDUFA is 12/8/15): http://finance.yahoo.com/news/alexion-receives-notification-pdufa-date-110000590.html ALXN acquired Kanuma in the controversial GEVA buyout (#msg-113395760).